Tag: EMA

The European Medicines Agency entered into the phase 3 of its business continuity plan(BCP) on 1 October 2018. This allows the Agency to safeguard core activities related to the evaluation and supervision of medicines, while it has to intensify its preparations for the physical move to Amsterdam in March 2019 and cope with significant staff […]

How EMA monitors medicines once they are on the market After its authorization a medicine is used by many patients, often together with other medicines. After some time, certain side effects may emerge that have not previously been identified because no medicine is a 100% safe. It is therefore essential that the safety of all […]

The European Medicines Agency (EMA) and the European Commission are currently providing guidance to help pharmaceutical companies responsible for medicines to be prepared for the UK withdrawal from the EUwhich will become a third country as of 30 March 2019. The objective is to ensure that companies are ready to take the necessary steps to enable undisrupted supply of their medicines […]